文献速递消化系统肿瘤

三药联合生物制剂后切除的结直肠癌肝转移免疫微环境预后影响

Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
PubMed 文献 · Eur J Cancer · 2020-06-15

该汇总分析纳入五项前瞻性试验中106例接受三药化疗联合贝伐珠单抗或西妥昔单抗后行二次切除的结直肠癌肝转移患者,评估肿瘤微环境免疫参数。结果显示基质COX-2、HLA和PD1表达是RFS独立预后因素,炎症评分阳性者RFS和OS更长,CD4/CD8评分及联合评分也显示预后价值。

要点

  • 基质COX-2、HLA、PD1表达是RFS独立预后因素。
  • 炎症评分阳性者RFS 25.5 vs 9.8个月,OS 64.3 vs 37.7个月。
  • CD4/CD8高表达者术后OS更优(未达到 vs 41.6个月)。

核心结论

  • 免疫微环境是三药联合生物制剂后切除患者的独立生存预测因素。
  • 炎症评分、CD4/CD8评分及联合评分需进一步研究确认预后价值。

研究设计与样本

  • 汇总五项一线非营利临床试验,纳入106例接受三药化疗联合贝伐珠单抗(N=59)或西妥昔单抗(N=47)后行二次切除的结直肠癌肝转移患者。
  • 对肿瘤细胞和微环境进行广泛免疫组化评估。

主要发现

  • 免疫参数在不同靶向药物、RAS/BRAF突变状态及病理或RECIST反应间无实质差异。
  • 基质COX-2(p=0.002)、HLA(p=0.003)和PD1(p=0.002)为RFS独立预后因素,对术后OS有阳性趋势。
  • 炎症评分阳性者RFS为25.5 vs 9.8个月(p<0.001),术后OS为64.3 vs 37.7个月(p=0.003)。
  • CD4/CD8评分高者术后OS更优(未达到 vs 41.6个月,p=0.032)。
  • 炎症评分与CD4/CD8评分联合评分显示明确预后作用。

临床怎么用

  • 可考虑评估肝转移灶免疫微环境参数以辅助预后分层。
  • 炎症评分、CD4/CD8评分及联合评分可能指导术后随访策略。

局限性

  • 回顾性汇总分析,样本量有限(106例)。
  • 免疫评分需在前瞻性研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune-contexture of tumour microenvironment (TME) influences prognosis of colorectal cancer (CRC) patients and can be altered by cytotoxic and targeted agents. Limited data are available regarding the immune-TME of CRC after treatment. METHODS: An extensive immunohistochemistry evaluation of immunological parameters on tumour cells and TME of colorectal liver metastases from 106 patients who underwent secondary resection, after receiving triplets FOLFOXIRI (5-fluorouracil, oxaliplatin and irinotecan) or COI (capecitabine, oxaliplatin and irinotecan) plus bevacizumab (N = 59) or cetuximab (N = 47) in five first-line no-profit clinical trials was performed. RESULTS: No substantial differences were reported in immunological parameters according to administered targeted agent, RAS/BRAF mutational status and histopathological or Response Evaluation Criteria in Solid Tumours response. Stromal expression of Cyclooxygenase-2 (COX-2) (p = 0.002), Human leukocyte antigen (HLA) (p = 0.003) and Programmed cell death protein 1 (PD1) (p = 0.002) were independent prognostic factors for longer relapse-free survival (RFS) at multivariate analysis with a positive trend for post-resection overall survival (OS). Patients whose metastases expressed stromal COX-2, HLA and PD1 (inflamed-score positive) reported longer RFS (25.5 versus 9.8 months; p < 0.001) and post-resection OS (64.3 versus 37.7 months; p = 0.003) as compared with others. In addition, patients with higher expression of CD4 and CD8 T-cells in tumour core and invasive margin (CD4/CD8-score) showed a better post-resection OS (not-reached versus 41.6 months; p = 0.032). A combined score of inflamed-score and CD4/CD8-score (combo-score) showed a clear prognostic role. CONCLUSIONS: The present study emphasises the role of immune-TME as independent predictor of survival in patients resected after triplets plus biologic. Inflamed-, CD4/C8- and combo-scores should be confirmed as prognostic factors in further studies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Moretto R, Corallo S, Belfiore A, et al. Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. Eur J Cancer. 2020. PMID: 32554314. doi:10.1016/j.ejca.2020.04.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。